Reply to "Erbitux® (cetuximab): make your voice count!"

Appraisal Committee's preliminary recommendations
  • Cetuximab in combination with radiotherapy is recommended as a treatment option only for patients with locally advanced squamous cell cancer of the head and neck whose Karnofsky performance-status score is 90% or greater and for whom all forms of platinum-based chemoradiotherapy treatment are contraindicated.
  • People currently receiving cetuximab in combination with radiotherapy for the treatment of locally advanced squamous cell cancer of the head and neck who do not meet the criteria outlined in section 1.1 should have the option to continue therapy until they and their clinicians consider it appropriate to stop


Note that this document does not constitute the Institute's formal guidance on this technology. The recommendations made in Section 1 are preliminary and may change after consultation.

Ref: http://www.nice.org.uk/guidance/index.jsp?action=folder&o=39184
The key dates for this appraisal are:
Closing date for comments: 4 March 2008

Next Appraisal Committee meeting: 12 March 2008

Related News:
×
×
×
×